clinical trial · NCT07224360
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
CSL Behring·phase2·recruiting·n = 63
Sickle Cell DiseaseAnumigilimabPlacebo
brief summary
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
started
Feb 2, 2026
primary completion
Jun 29, 2028
completion
Jun 29, 2028
last updated
Feb 20, 2026
official title
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol